Cite
Kirchner MA, Holzgreve A, Brendel M, et al. PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook. Front Oncol. 2021;11:774017doi: 10.3389/fonc.2021.774017.
Kirchner, M. A., Holzgreve, A., Brendel, M., Orth, M., Ruf, V. C., Steiger, K., Pötter, D., Gold, L., Unterrainer, M., Mittlmeier, L. M., Barci, E., Kälin, R. E., Glass, R., Lindner, S., Kaiser, L., Maas, J., von Baumgarten, L., Ilhan, H., Belka, C., Notni, J., Bartenstein, P., Lauber, K., & Albert, N. L. (2021). PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook. Frontiers in oncology, 11774017. https://doi.org/10.3389/fonc.2021.774017
Kirchner, Maximilian A, et al. "PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook." Frontiers in oncology vol. 11 (2021): 774017. doi: https://doi.org/10.3389/fonc.2021.774017
Kirchner MA, Holzgreve A, Brendel M, Orth M, Ruf VC, Steiger K, Pötter D, Gold L, Unterrainer M, Mittlmeier LM, Barci E, Kälin RE, Glass R, Lindner S, Kaiser L, Maas J, von Baumgarten L, Ilhan H, Belka C, Notni J, Bartenstein P, Lauber K, Albert NL. PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook. Front Oncol. 2021 Nov 17;11:774017. doi: 10.3389/fonc.2021.774017. eCollection 2021. PMID: 34869017; PMCID: PMC8635528.
Copy
Download .nbib